Drugs / 90Y-DOTA-BC8
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01300572 | Jan 2012 → Oct 2017 | acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-DOTA-BC8 | “A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute...” NCT01300572 ↗ |
| Known as | 90Y-BC8 | “This phase I trial studies the side effects and maximum tolerated dose of yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by...” NCT01300572 ↗ |
| Modality | Monoclonal antibody | “yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8)” NCT01300572 ↗ |
| Route | Intravenous | “Given via central line (therapeutic dose)” NCT01300572 ↗ |